Triage Test for All Oral Drug Resistant Tuberculosis Regimen: T2RiAD study
The overarching aim of the proposal is to evaluate the effectiveness, operational feasibility, acceptability, and cost-effectiveness of implementing the Xpert MTB/XDR for rapid triage and selection of all-oral regimens for DR-TB.
Ongoing transmission of drug-resistant tuberculosis (DR-TB) remains a major obstacle to the United Nations (UN) End-TB strategy. The TriAD study is a multi-center, multi-country Prospective Pragmatic Cohort study assessing the effectiveness, feasibility, acceptability, and cost-effectiveness of implementing the GeneXpert MTB/XDR (Xpert XDR; Cepheid) assay for rapid triage-and-treatment of DR-TB.
The TriAD study will provide an approach for improving diagnosis and treatment of every patient with DR-TB. This study will generate real-world evidence, guiding delivery and uptake of novel diagnostics and all-oral regimens, that has the potential to alter the course of the DR-TB epidemic.
AIGHD Research Lead
Dr. Sabine Hermans
Centre for the Aids Programme of Research in South Africa (South Africa)
Foundation for Innovative New Diagnostics (Switzerland)
Wits Health Consortium (South Africa)
National Institute for Medical Research (United Republic of Tanzania)
The University Court of the University of St Andrews (United Kingdom)
Ospedale San Raffaele (Italy)
Koninklijke Nederlandse Centrale Vereniging tot Bestrijding der Tuberculose (Netherlands)
Institute of Human Virology Nigeria (Nigeria)
Ethiopian Public Health Institute (Ethiopia)
Amsterdam Institute for Global Health and Development (Netherlands)
The Global Alliance for TB Drug Development (United States)
Mark van Knegsel (email@example.com)
United Republic of Tanzania